Candel Therapeutics (CADL) Total Liabilities: 2020-2023
Historic Total Liabilities for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $27.0 million.
- Candel Therapeutics' Total Liabilities fell 17.76% to $27.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $27.0 million, marking a year-over-year decrease of 17.76%. This contributed to the annual value of $30.0 million for FY2022, which is 19.58% up from last year.
- Per Candel Therapeutics' latest filing, its Total Liabilities stood at $27.0 million for Q3 2023, which was down 3.21% from $27.9 million recorded in Q2 2023.
- Over the past 5 years, Candel Therapeutics' Total Liabilities peaked at $37.8 million during Q1 2022, and registered a low of $12.8 million during Q4 2020.
- Over the past 3 years, Candel Therapeutics' median Total Liabilities value was $29.0 million (recorded in 2022), while the average stood at $29.9 million.
- Its Total Liabilities has fluctuated over the past 5 years, first surged by 96.09% in 2021, then dropped by 27.02% in 2023.
- Candel Therapeutics' Total Liabilities (Quarterly) stood at $12.8 million in 2020, then surged by 96.09% to $25.1 million in 2021, then climbed by 19.58% to $30.0 million in 2022, then fell by 17.76% to $27.0 million in 2023.
- Its last three reported values are $27.0 million in Q3 2023, $27.9 million for Q2 2023, and $27.6 million during Q1 2023.